Clinical Research Consultants
Kansas City, Missouri 64111-5964
1 studies enrolling now · 12 studies all time
What they study most
Anemia of Chronic Kidney Disease, C3 Glomerulonephritis, Chronic Kidney Disease, Chronic Kidney Diseases, Dense Deposit Disease, Diabetes Complications, Diabetes Mellitus, Diabetic Nephropathies, End Stage Kidney Disease, Endocrine System Diseases, Focal Segmental Nephrosis, Glomerulonephritis
Studies at this site
- Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) — Recruiting now
- A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease — Recruiting now
- Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD) — Stopped early
- Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% — Completed
- Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies — Completed
- A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia — Completed
- An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases — Stopped early
- A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease — Stopped early
- A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia — Completed
- A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN) — Stopped early
- KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial) — Completed
- KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD — Completed